

## Journal of Hepatology

### CTAT methods

Tables for a “Complete, Transparent, Accurate and Timely account” (CTAT) are now mandatory for all revised submissions. The aim is to enhance the reproducibility of methods.

- Only include the parts relevant to your study
- Refer to the CTAT in the main text as ‘Supplementary CTAT Table’
- Do not add subheadings
- Add as many rows as needed to include all information
- Only include one item per row

If the CTAT form is not relevant to your study, please outline the reasons why:

--

#### 1.1 Antibodies

Name	Citation	Supplier	Cat no.	Clone no.
Anti-Integrin $\alpha$ v	PMID: 29743605	Santa Cruz	Sc-9969	N/A
Anti-Integrin $\beta$ 3	PMID: 22270917	Santa Cruz	Sc-46655	N/A
Anti-Integrin $\alpha$ v/ $\beta$ 3	PMID: 30517646	Santa Cruz	Sc-7312	N/A
Anti- $\alpha$ -SMA	PMID: 30651793	Abcam	Ab5694	N/A
Anti-CD68	PMID: 30237493	Cell Signaling Technology	76437S	N/A
$\beta$ -actin	PMID: 16424156	Sigma Life Science	A2228	N/A

#### 1.2 Cell lines

Name	Citation	Supplier	Cat no.	Passage no.	Authentication test method
N/A	N/A	N/A	N/A	N/A	N/A

#### 1.3 Organisms

Name	Citation	Supplier	Strain	Sex	Age	Overall n number
CD1	N/A	Charles River Laboratory	CD1	Male	10 Weeks	40

#### 1.4 Sequence based reagents

Name	Sequence	Supplier
IL-1 $\beta$	GAACCAAGCAACGACAAA GCAGACTCAAACCTCCACT	IBT

TGF- $\beta$ 1	CTCCCGTGGCTTCTAGTGC GCCTTAGTTTGGACAGGATCTG	IBT
Vimentin	CTGTACGAGGAGGAGATGCG AATTTCTTCCTGCAAGGATT	IBT
TIMP1	GCATGGACATTTATTCTCCACTGT TCTCTAGGAGCCCCGATCTG	IBT
$\alpha$ -SMA	TCAGCGCCTCCAGTTCCT AAAAAAAAACCACGAGTAACAAATCAA	IBT
COL1A1	TTCACCTACAGCACGCTTGTG GATGACTGTCTTGCCCCAAGT	IBT
GAPDH	CCATGGAGA AGGCTGGGG CAAAGTTGTCATGGATGACC	IBT

## 1.5 Biological samples

Description	Source	Identifier
Tissues, Blood	Mouse	N/A
Tissues	Human	N/A

## 1.6 Deposited data

Name of repository	Identifier	Link
N/A	N/A	N/A

## 1.7 Software

Software name	Manufacturer	Version
Image Lab	Bio-rad	5.2.1
ImageJ	NIH	1.8
Prism	GraphPad	6.0
Excel	Microsoft	2016
QIIME	SCIKIT-BIO	1.9
ASIProVM	Siemens	N/A
Inveon	Siemens	N/A

## 1.8 Other (e.g. drugs, proteins, vectors etc.)

FITC-E(PEG4-RGDfK) <sub>2</sub>	[ <sup>18</sup> F]-Alfatide	

## 1.9 Please provide the details of the corresponding methods author for the manuscript:

<p>Steven Liang, PhD            Email: <a href="mailto:Liang.Steven@mgh.harvard.edu">Liang.Steven@mgh.harvard.edu</a>            Phone: +1-617-230-5491            Fax: +1-617-726-6165            Address: 55 Fruit St., Boston, MA, 02114, USA</p>
--

**2.0** Please confirm for randomised controlled trials all versions of the clinical protocol are included in the submission. These will be published online as supplementary information.

N/A
-----